Patient Opportunity Trust Class IS MVISX

Medalist Rating as of | See Patient Capital Investment Hub
  • NAV / 1-Day Return 60.67  /  +0.12 %
  • Total Assets 2.0B
  • Adj. Expense Ratio
    0.880%
  • Expense Ratio 1.320%
  • Distribution Fee Level Above Average
  • Share Class Type Institutional
  • Category Mid-Cap Value
  • Investment Style Mid Value
  • Min. Initial Investment 1M
  • Status Open
  • TTM Yield 0.17%
  • Turnover 27%

USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:45 AM GMT+0

Morningstar’s Analysis MVISX

Will MVISX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

In good hands.

Analyst David Carey

David Carey

Analyst

Summary

Increased conviction in Patient Opportunity’s lead manager and supporting cast warrants a People Pillar upgrade to Above Average from Average, while its Process Pillar remains Average.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings MVISX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 48.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Royalty Pharma PLC Class A

6.31 120M
Healthcare

Citigroup Inc

5.96 113M
Financial Services

Alphabet Inc Class A

5.75 109M
Communication Services

QXO Inc

5.11 97M
Industrials

Amazon.com Inc

4.98 95M
Consumer Cyclical

NVIDIA Corp

4.59 87M
Technology

UnitedHealth Group Inc

4.27 81M
Healthcare

Energy Transfer LP

4.26 81M
Energy

IAC Inc Ordinary Shares - New

3.79 72M
Communication Services

Norwegian Cruise Line Holdings Ltd

3.74 71M
Consumer Cyclical

Sponsor Center